Skip to main content
PMC home page
Journal of Medical Toxicology logoLink to Journal of Medical Toxicology
. 2010 Apr 1;6(4):393–397. doi: 10.1007/s13181-010-0051-4

A Controlled Clinical Trial of A Novel Antivenom in Patients Envenomed by Bungarus multicinctus

Ha Tran Hung 1, Jonas Höjer 2,✉, Trinh Xuan Kiem 1, Nguyen Thi Du 1
PMCID: PMC3550464  PMID: 20358414

Abstract

In northern Vietnam, a majority of severely envenomed patients are bitten by Bungarus multicinctus. Hitherto, these victims have received supportive care only. The aims of this study were to assess the possible efficacy and side effects of a new antivenom. This trial (ClinicalTrials.gov Identifier: NCT00811239) was performed during 2004–2006 at an ICU in Hanoi. For ethical reasons, the study was not randomized. All patients who fulfilled the inclusion criteria during 2004–2005 were prospectively enrolled, carefully recorded, and treated with optimal supportive therapy (control group). The patients who entered the study 2006 were treated with antivenom in addition to supportive care (antivenom group). The inclusion criteria were: envenomation by B. multicinctus, presence of systemic envenomation, and (during 2006) provision of written informed consent. Predefined endpoints were number of patients requiring mechanical ventilation, duration of mechanical ventilation, length of ICU stay, duration of muscle paralysis, and number of patients with ventilator-associated pneumonia. Eighty-one patients were included, 54 during 2004–2005 and 27 during 2006. Baseline characteristics were similar in the groups. The antivenom-group patients had a shorter duration of muscle paralysis of the limbs (p < 0.001), of the diaphragm (p < 0.001), and of ptosis (p < 0.001). The duration of mechanical ventilation and length of ICU stay were shorter in the antivenom group (p < 0.001). The rate of ventilator-associated pneumonia was lower in the antivenom group (p < 0.02). However, the relative number of patients requiring mechanical ventilation was not reduced in the antivenom group. The rate of adverse reactions to the antivenom was 7.4%. A favorable efficacy and acceptable safety of this antivenom were demonstrated.

Keywords: Antivenom, Snakebite, Bungarus multicinctus, Vietnam

Full Text

The Full Text of this article is available as a PDF (109.1 KB).

Acknowledgment

The financial support for the project from Sida's Secretariat for Research Cooperation for the bilateral cooperation between Vietnam and Sweden is gratefully acknowledged.

Footnotes

Previous presentation: no data of this manuscript has previously been presented.

References

  • 1.Warrell DA. Clinical toxicology of snakebite in Asia. In: Meier J, White J, editors. Handbook of clinical toxicology of animal venoms and poisons. Florida: CRC; 1995. pp. 493–594. [Google Scholar]
  • 2.Cheng AC, Winkel KD. Snakebite and antivenoms in the Asia-Pacific: wokabaut wantaim, raka hebou ("walking together") MJA. 2001;175:648–651. doi: 10.5694/j.1326-5377.2001.tb143762.x. [DOI] [PubMed] [Google Scholar]
  • 3.Chan JC, Cockram CS, Buckley T, Young K, Kay R, Tomlinson B. Envenoming by Bungarus multicinctus (many-banded krait) in Hong Kong. J Trop Med Hyg. 1995;98:457–460. [PubMed] [Google Scholar]
  • 4.Rowan E. What does β-bungarotoxin do at the neuromuscular junction? Toxicon. 2001;39:107–118. doi: 10.1016/S0041-0101(00)00159-8. [DOI] [PubMed] [Google Scholar]
  • 5.Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med. 2001;37:181–188. doi: 10.1067/mem.2001.113372. [DOI] [PubMed] [Google Scholar]
  • 6.White J. Envenoming and antivenom use in Australia. Toxicon. 1998;36:1483–1492. doi: 10.1016/S0041-0101(98)00138-X. [DOI] [PubMed] [Google Scholar]
  • 7.Karlson-Stiber C, Salmonson H, Persson H. A nationwide study of Vipera berus bites during one year—epidemiology and mortality of 231 cases. Clin Toxicol. 2006;44:25–30. doi: 10.1080/15563650500394597. [DOI] [PubMed] [Google Scholar]
  • 8.Lalloo DG, Theakston RDG. Antivenom tables. J Toxicol Clin Toxicol. 2003;41:317–327. doi: 10.1081/CLT-120021117. [DOI] [PubMed] [Google Scholar]
  • 9.Sawai Y, Kawamura Y, Toriba M, Kobayashi T, Wang NP, Li CB, et al. An epidemiological study on the snakebites in Guangxi Zhuang autonomous region, China in 1990. The Snake. 1992;24:1–15. [Google Scholar]
  • 10.Warrel DA, Looareesuwan S, White NJ, Theakston RD, Warrel MJ, Kosakarn W, et al. Severe neurotoxic envenoming by the Malayan krait Bungarus candidus (Linnaeus): response to antivenom and anticholinesterase. BMJ. 1983;286:678–680. doi: 10.1136/bmj.286.6366.678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Theakson DG, Phillips RE, Warrel DA, Galagedera Y, Abeysekera DT, Dissanayaka P, et al. Envenoming by the common krait (Bungarus caeruleus) and Sri Lanka cobra (Najar najar najar): efficacy and complications of therapy by Haffkine antivenom. Trans R Soc Trop Med Hyg. 1990;84:301–308. doi: 10.1016/0035-9203(90)90297-R. [DOI] [PubMed] [Google Scholar]
  • 12.Persson H, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36:205–213. doi: 10.3109/15563659809028940. [DOI] [PubMed] [Google Scholar]
  • 13.Hung HT, Höjer J, Du NT. Clinical features of 60 consecutive ICU-treated patients envenomed by Bungarus multicinctus. Southeast Asia J Trop Med Public Health. 2009;40:518–524. [PubMed] [Google Scholar]
  • 14.Heard K, O'Malley GF, Dart RC. Antivenom therapy in the Americas. Drugs. 1999;58:5–15. doi: 10.2165/00003495-199958010-00002. [DOI] [PubMed] [Google Scholar]
  • 15.Malasit P, Warrel DA, Chanthavanich P, Viravan C, Mongkolsapaya J, Singhthong B, et al. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reaction in victims of snake bites. BMJ. 1986;292:17–20. doi: 10.1136/bmj.292.6512.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Weisman RS, Lizarralde SS, Thompson V. Snake and spider antivenin: risks and benefits of therapy. J Florida M A. 1996;83:192–195. [PubMed] [Google Scholar]
  • 17.Lalloo DG, Theakston RDG. Snake antivenoms. J Toxicol Clin Toxicol. 2003;41:277–290. doi: 10.1081/CLT-120021113. [DOI] [PubMed] [Google Scholar]
  • 18.Açikalin A, Gökel Y, Kuvandik G, Duru M, Köseoglu Z, Satar S. The efficacy of low-dose antivenom therapy on morbidity and mortality in snakebite cases. Am J Emerg Med. 2008;26:402–407. doi: 10.1016/j.ajem.2007.06.017. [DOI] [PubMed] [Google Scholar]
  • 19.Tariang DD, Philip PJ, Alexander G, Macaden S, Jeyaseelan L, Peter JV, et al. Randomized controlled trial on the effective dose of anti-snake venom in cases of snake bite with systematic envenomation. JAPI. 1999;47:369–371. [PubMed] [Google Scholar]
  • 20.Chippaux JP, Lang J, Eddine SA, Fagot P, Rage V, Peyrieux JC, et al. Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans R Soc Trop Med Hyg. 1998;92:657–662. doi: 10.1016/S0035-9203(98)90802-1. [DOI] [PubMed] [Google Scholar]
  • 21.Karlson-Stiber C, Persson H, Heath A, Smith D, Al-Abdulla IH, Sjöström L. First clinical experience with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. JIM. 1997;241:53–58. doi: 10.1046/j.1365-2796.1997.80896000.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Toxicology are provided here courtesy of Springer

RESOURCES